This has paved the way for investigation of combinatorial approaches with immune checkpoint inhibition in different cancer types, and numerous reports have shown clinical benefit of the combination of RT and PD-1/PD-L1 blockade in melanoma [30], non-small cell lung cancer (NSCLC) [31], Hodgkin lymphoma [32], renal cell carcinoma (RCC) [33]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.